News | Hypertension | January 08, 2019

Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk

Researchers found patients with a progression of abnormalities in periventricular white matter disease on MRI had a six-fold increased risk of cognitive decline

Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk

January 8, 2019 – Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of cognitive impairment despite taking medication to lower their blood pressure, according to new research in the American Heart Association’s journal Hypertension.1

High blood pressure has been linked to an increased risk for dementia, but what’s unclear is what kinds of subtle negative changes take place in the brain that may affect cognitive function. Finding new ways to detect minor types of cognitive impairment may help determine who is at risk for early-stage dementia.

In this study, researchers looked at 345 men and women with a median age of 65 who had high blood pressure. Patients underwent brain magnetic resonance imaging (MRI) scans, were tested in cognitive function areas including execution, memory and attention, and were followed for about four years. Patients’ average blood pressure during follow-up was 144.5/76.5 mm Hg. The American Heart Association/American College of Cardiology 2017 hypertension guidelines revised the definition of hypertension and classified it as a blood pressure reading of 130/80 mm Hg instead of 140/90.

To understand what was going on in the brain, researchers looked at the brain’s white matter. White matter is important because it connects different regions of the brain, serving as a kind of infrastructure. Specifically, researchers looked at periventricular white matter, located in the central part of the brain. Periventricular white matter acts as a bridge between distant brain regions and serves an important role in cognitive function. Lesions or abnormalities found in periventricular white matter could signal cognitive impairment.

During the study, 9 percent of the group developed mild cognitive impairment which may increase the risk for dementia. There was also a connection for periventricular white matter changes and the risk of mild cognitive impairment. Researchers found that patients with a progression of periventricular white matter abnormalities showed a six-fold increased risk of mild cognitive decline.

The study observed that the progression of periventricular white matter abnormalities aligned with cognitive decline in global and executive function; small vessel bleeding in the brain was found to be related to a decline in attention.

Although the development of brain lesions may be considered “silent” conditions in which patients do not feel or are unaware of symptoms, if left untreated, the risks of more severe forms of cognitive decline may increase. Researchers say more study is needed to better understand how periventricular white matter changes triggers cognitive decline.

“The brain is an organ exposed to a high volume of blood flow and it is very vulnerable to sustained high blood pressure levels, and this might be happening silently or with mild symptoms, but that doesn’t mean there aren’t consequences,” said lead author Joan Jiménez Balado, Ph.D. student, psychologist, M.Sc. in neuroscience at the Institut de Recerca Hospital Vall d'Hebron in Barcelona, Spain. “High blood pressure and its consequences are really ‘covert’ diseases that tend to progress if it is not well managed.”

For more information: www.ahajournals.org/journal/hyp

Reference

1. Jiménez-Balado J., Riba-Llena I., Abril O., et al. Cognitive Impact of Cerebral Small Vessel Disease Changes in Patients With Hypertension. Hypertension, Jan. 4, 2019. https://doi.org/10.1161/HYPERTENSIONAHA.118.12090

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init